Lantheus (NASDAQ:LNTH) Receives “Market Outperform” Rating from JMP Securities

Lantheus (NASDAQ:LNTH)‘s stock had its “market outperform” rating restated by stock analysts at JMP Securities in a report issued on Tuesday,Benzinga reports. They currently have a $112.00 price objective on the medical equipment provider’s stock. JMP Securities’ target price suggests a potential upside of 19.40% from the company’s previous close.

Several other research firms also recently issued reports on LNTH. The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, Truist Financial reaffirmed a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Price Performance

NASDAQ:LNTH traded down $0.85 during trading hours on Tuesday, hitting $93.80. 28,411 shares of the company were exchanged, compared to its average volume of 759,900. Lantheus has a 52-week low of $50.20 and a 52-week high of $126.89. The stock has a market capitalization of $6.52 billion, a price-to-earnings ratio of 15.61 and a beta of 0.46. The company’s 50 day moving average price is $89.98 and its 200-day moving average price is $99.78.

Institutional Investors Weigh In On Lantheus

Several hedge funds have recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus during the 3rd quarter worth approximately $25,000. Signaturefd LLC raised its position in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the period. Nkcfo LLC purchased a new position in Lantheus during the second quarter valued at $47,000. UMB Bank n.a. grew its position in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares during the period. Finally, Kathleen S. Wright Associates Inc. purchased a new stake in shares of Lantheus during the third quarter worth about $51,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.